Design Therapeutics (DSGN) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free DSGN Stock Alerts $4.41 -0.09 (-2.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Design Therapeutics, Inc. (NASDAQ:DSGN) Lifted by AnalystMay 10, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic ReviewMay 10, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Strategic Updates and Financial ReviewMay 9, 2024 | americanbankingnews.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Hold" from AnalystsMay 9, 2024 | msn.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024May 8, 2024 | globenewswire.comDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program MilestonesMay 8, 2024 | americanbankingnews.comDesign Therapeutics (NASDAQ:DSGN) Upgraded to Overweight at Piper SandlerMay 7, 2024 | msn.comPiper Sandler Upgrades Design Therapeutics (DSGN)May 7, 2024 | msn.comDesign Therapeutics climbs as Piper Sandler upgrades on pipelineMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Design Therapeutics’ Innovative Pipeline and Solid FinancialsMay 7, 2024 | marketbeat.comPiper Sandler Upgrades Design Therapeutics (NASDAQ:DSGN) to "Overweight"Piper Sandler upgraded Design Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $6.00 to $12.00 in a report on Tuesday.May 7, 2024 | globenewswire.comDesign Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMay 1, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Sees Significant Growth in Short InterestDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,390,000 shares, a growth of 7.2% from the March 31st total of 2,230,000 shares. Based on an average daily trading volume, of 258,100 shares, the short-interest ratio is currently 9.3 days. Approximately 7.2% of the company's stock are short sold.April 24, 2024 | marketbeat.com1,029,478 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BML Capital Management LLCBML Capital Management LLC bought a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,029,478 shares ofMarch 31, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest UpdateDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 2,140,000 shares, a decline of 24.9% from the February 29th total of 2,850,000 shares. Approximately 6.5% of the shares of the company are sold short. Based on an average daily volume of 259,700 shares, the short-interest ratio is presently 8.2 days.March 27, 2024 | finance.yahoo.comIndependent Director of Design Therapeutics Picks Up 88% More StockMarch 26, 2024 | msn.comDesign Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Purchases 9,156 SharesMarch 26, 2024 | insidertrades.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in StockMarch 25, 2024 | marketbeat.comJohn P. Schmid Acquires 9,156 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director John P. Schmid purchased 9,156 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the acquisition, the director now owns 9,156 shares in the company, valued at approximately $33,144.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 22, 2024 | marketbeat.comDesign Therapeutics, Inc. to Post FY2026 Earnings of ($1.27) Per Share, Wedbush Forecasts (NASDAQ:DSGN)Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Analysts at Wedbush issued their FY2026 earnings estimates for shares of Design Therapeutics in a research report issued on Wednesday, March 20th. Wedbush analyst L. Chico expects that the company will post earnings of ($1.27) per share forMarch 21, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)March 21, 2024 | markets.businessinsider.comHold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program UpdatesMarch 21, 2024 | marketbeat.comLeerink Partnrs Comments on Design Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:DSGN)Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Equities researchers at Leerink Partnrs issued their FY2025 earnings per share (EPS) estimates for Design Therapeutics in a report issued on Tuesday, March 19th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earninMarch 20, 2024 | stockhouse.comDesign Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | marketbeat.comDesign Therapeutics (NASDAQ:DSGN) Receives Sector Perform Rating from Royal Bank of CanadaRoyal Bank of Canada restated a "sector perform" rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday.March 20, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Rating of "Hold" from BrokeragesDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been given a consensus recommendation of "Hold" by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation. The average 12-mMarch 19, 2024 | investorplace.comDSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023March 19, 2024 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline ProgressMarch 19, 2024 | globenewswire.comDesign Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | investing.comDesign Therapeutics Inc (DSGN)March 18, 2024 | benzinga.comEarnings Preview For Design TherapeuticsMarch 15, 2024 | finance.yahoo.comDSGN Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comDSGN Jul 2024 2.500 putMarch 12, 2024 | globenewswire.comDesign Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateMarch 11, 2024 | marketbeat.comDesign Therapeutics (DSGN) Set to Announce Earnings on TuesdayDesign Therapeutics (NASDAQ:DSGN) will be releasing earnings on Tuesday, March 12, Yahoo Finance reports.March 6, 2024 | marketbeat.comRTW Investments LP Boosts Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)RTW Investments LP boosted its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 60.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,512,986 shares of the company's stock after acquiring an additFebruary 9, 2024 | benzinga.comSR ONE CAPITAL PARTNERS I, LP's Net WorthFebruary 7, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Receives Average Recommendation of "Hold" from AnalystsShares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have earned a consensus recommendation of "Hold" from the seven brokerages that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating. The average 1-year price target amonJanuary 15, 2024 | marketbeat.comShort Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Grows By 9.7%Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,820,000 shares, an increase of 9.7% from the December 15th total of 2,570,000 shares. Based on an average trading volume of 426,300 shares, the days-to-cover ratio is currently 6.6 days. Currently, 8.7% of the shares of the company are short sold.January 13, 2024 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Hold" by AnalystsDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has earned an average rating of "Hold" from the seven ratings firms that are covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation. The average twelve-month target priJanuary 1, 2024 | marketbeat.comShort Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Declines By 19.2%Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,570,000 shares, a decline of 19.2% from the November 30th total of 3,180,000 shares. Currently, 7.9% of the shares of the company are short sold. Based on an average daily volume of 422,000 shares, the short-interest ratio is currently 6.1 days.December 19, 2023 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Hold" by AnalystsDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) has been given an average rating of "Hold" by the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating. The average 12-month price target amDecember 18, 2023 | finance.yahoo.comDesign Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should KnowDecember 7, 2023 | morningstar.comDesign Therapeutics Inc DSGNNovember 25, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Design Therapeutics StockNovember 16, 2023 | markets.businessinsider.comHold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial UncertaintiesNovember 14, 2023 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic UpdateNovember 13, 2023 | finance.yahoo.comDesign Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024September 15, 2023 | marketbeat.comShort Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 42.2%Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the recipient of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 2,300,000 shares, a drop of 42.2% from the August 15th total of 3,980,000 shares. Currently, 7.1% of the company's stock are short sold. Based on an average daily trading volume, of 893,000 shares, the short-interest ratio is currently 2.6 days. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made … Click here to see the presentation now. DSGN Media Mentions By Week DSGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSGN News Sentiment▼0.890.50▲Average Medical News Sentiment DSGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSGN Articles This Week▼41▲DSGN Articles Average Week Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMMP News AKBA News ALDX News PYXS News OMER News TSVT News GTHX News EPIX News FHTX News EBS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DSGN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceA once-in-a-century investment opportunityStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
